Leveraging Human Genetics to Advance Precision Medicine in CKD: Translating APOL1 & Amino Acid Transporter Insights into Clinical Progress
- Defining distinct CKD-susceptible populations through APOL1 genetic variants and exploring the potential to modulate this biology with a small-molecule inhibitor supported by favorable Phase 1 safety and pharmacokinetic results
- Interrogating the genetic and biological role of the amino acid transporter BoAT1 (SLC6A19) in CKD progression to uncover new opportunities for therapeutic intervention beyond current standard-of-care approaches
- Presenting Phase 1 clinical data and mechanistic hypotheses linking target modulation to improved kidney outcomes
- Leveraging human genetics and biomarker datasets to validate target inhibition, confirm efficacy signals, and enable precision-driven clinical development in CKD populations